Eli Lilly's stock is undervalued; defensive healthcare stocks shine amid uncertainty, and Eli Lilly drives growth. Click here ...

(Reuters) -OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other ...

In a report released on March 14, Akash Tewari from Jefferies maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a ...

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Scholar Rock Holding (SRRK – Research ...

Adults taking the novel once-daily oral pill for plaque psoriasis had significantly higher rates of clear or almost clear ...

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

Irish government mounts a St. Patrick’s Day diplomatic offensive to try and calm Trump anger at ‘massive’ trade surplus.

In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.